Abstract 1543P
Background
Immunotherapy is effective in treating unresectable oesophageal squamous cell carcinoma (ESCC). This study aims to evaluate the clinical efficacy and safety of neoadjuvant camrelizumab combined with docetaxel and carboplatin in locally advanced ESCC.
Methods
All patients underwent surgery within 4-8 weeks after receiving 2 cycles of neoadjuvant therapy, which was camrelizumab (200mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (AUC= 5-6 IV Q3W). The pathological complete response (pCR) rate was the primary endpoint, and the secondary endpoints included R0 resection rate, objective response rate (ORR), disease-free survival (DFS), overall survival (OS) and safety.
Results
A total of 40 patients were included, of which 37 patients were evaluated, including 9 cases of complete response (CR), 18 cases of partial response (PR), 10 cases of stable disease (SD), and the ORR was 73% (27/37). The main adverse events were ALT/AST increase 52.5% (21/40), leukopenia 50% (20/40), nausea and vomiting 47.5% (19/40), bilirubin increase 40% (16/40), all of which were grade 1-2. One patient had Guillain-Barre Syndrome. Among these patients, 31 underwent surgical treatment, pCR rate was 22.6% (7/31), R0 resection rate was 100% (31/31), tumour regression grade (TRG) 0, 1, 2 and 3 were 22.6% (7/31), 16.1% (5/31), 22.6% (7/31) and 38.7% (12/31), respectively. The average operation time (310.0±57.6 minutes). The average intraoperative blood loss (136.1±41.4 ml) and the average hospitalization time after operation (10.9±2.7 days). The average number of resected lymph nodes (24.4±8.2). Surgery-related complications: anastomotic leakage 6.5% (2/31), pleural effusion 6.5% (2/31), cardiac arrhythmia 9.7% (3/31), pneumonia 3.2% (1/31), gastric emptying disorder 3.2% (1/31). The median follow-up time was 12 months (range 1–32 months). One patient had liver metastasis 21 months after surgery. No treatment-related death occurred.
Conclusions
Camrelizumab combined with docetaxel and carboplatin is effective and safe in the neoadjuvant treatment of locally advanced ESCC.
Clinical trial identification
ChiCTR2000033252.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21